A Phase 2a Study to Evaluate The Clinical Efficacy of JNJ-42756493, A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Patients With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Gastric Cancer, Esophageal Cancer Or Cholangiocarcinoma

Trial Profile

A Phase 2a Study to Evaluate The Clinical Efficacy of JNJ-42756493, A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Patients With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Gastric Cancer, Esophageal Cancer Or Cholangiocarcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2017

At a glance

  • Drugs Erdafitinib (Primary)
  • Indications Cholangiocarcinoma; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Urogenital cancer
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 17 Aug 2017 Planned number of patients changed from 75 to 55.
    • 17 Aug 2017 Planned End Date changed from 31 Dec 2019 to 31 Dec 2018.
    • 31 Mar 2017 Planned End Date changed from 1 Aug 2019 to 31 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top